World's Best Scientists 2026 revealed!
Aurélien Marabelle

Aurélien Marabelle

D-Index & Metrics

Immunology

D-Index
88
Citations
38224
World Ranking
1144
National Ranking
40

Medicine

D-Index
89
Citations
38467
World Ranking
12490
National Ranking
387

Overview

Aurélien Marabelle is affiliated with the Institut Gustave Roussy in France. Their research primarily focuses on oncology and immunology within the medical field.

The scientist's recent publications include:

  • Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study, 2020, The Lancet Oncology
  • Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19, 2020, Cell
  • Cancer vaccines: the next immunotherapy frontier, 2022, Nature Cancer
  • Mechanisms and therapeutic implications of hypermutation in gliomas, 2020, Nature
  • Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression, 2021, Nature Cancer

Their frequent co-authors include:

  • Stéphane Champiat
  • Capucine Baldini
  • Jean-Marie Michot
  • Christophe Massard
  • François-Xavier Danlos

Marabelle's publications appear mostly in venues such as:

  • Annals of Oncology
  • European Journal of Cancer
  • Journal of Clinical Oncology
  • Journal for ImmunoTherapy of Cancer
  • Cancer Research

The main field of study is Medicine, with a focus on several subfields including:

  • Oncology
  • Immunology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Pathology and Forensic Medicine

The scientist's main research topics encompass:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Cancer Genomics and Diagnostics
  • Immune Cell Function and Interaction
  • Genetic factors in colorectal cancer
  • Colorectal Cancer Treatments and Studies

Best Publications

  • Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

    Aurelien Marabelle;Dung T. Le;Paolo A. Ascierto;Anna Maria Di Giacomo

  • Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.

    Aurélien Marabelle;Marwan Fakih;Juanita Lopez;Manisha Shah

  • Immune-related adverse events with immune checkpoint blockade: a comprehensive review

    J.M. Michot;C. Bigenwald;S. Champiat;M. Collins

  • Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy

    J.M. Pitt;A. Marabelle;A. Marabelle;A. Eggermont;J.-C. Soria

  • Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

    Stephane Champiat;Stephane Champiat;Laurent Dercle;Samy Ammari;Christophe Massard

  • A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

    Roger Sun;Roger Sun;Elaine Johanna Limkin;Elaine Johanna Limkin;Maria Vakalopoulou;Maria Vakalopoulou;Laurent Dercle;Laurent Dercle

  • Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

    Celine Boutros;Ahmad Tarhini;Emilie Routier;Olivier Lambotte

  • Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

    S. Champiat;S. Champiat;O. Lambotte;E. Barreau;R. Belkhir

  • Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.

    Aymeric Silvin;Nicolas Chapuis;Garett Dunsmore;Anne-Gaëlle Goubet

  • Cancer vaccines: the next immunotherapy frontier

    Unknown

  • Mechanisms and therapeutic implications of hypermutation in gliomas.

    Mehdi Touat;Mehdi Touat;Mehdi Touat;Yvonne Y. Li;Yvonne Y. Li;Adam N. Boynton;Adam N. Boynton;Liam F. Spurr;Liam F. Spurr

  • Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.

    Eleonora De Martin;Jean-Marie Michot;Barbara Papouin;Stéphane Champiat

  • Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

    Lucile Vanhersecke;Maxime Brunet;Jean-Philippe Guégan;Christophe Rey

  • Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

    Unknown

  • Intratumoural administration and tumour tissue targeting of cancer immunotherapies

    Ignacio Melero;Eduardo Castanon;Maite Alvarez;Stephane Champiat;Stephane Champiat;Stephane Champiat

  • Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

    Aurélien Marabelle;Holbrook Kohrt;Idit Sagiv-Barfi;Bahareh Ajami

  • Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study

    Unknown

  • Hyperprogressive disease: recognizing a novel pattern to improve patient management

    Stéphane Champiat;Roberto Ferrara;Christophe Massard;Benjamin Besse

  • Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report.

    Jean-Marie Michot;Laurence Albiges;Nathalie Chaput;Veronique Saada

  • Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.

    Audrey Simonaggio;Jean Marie Michot;Anne Laure Voisin;Jérome Le Pavec

  • Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

    Holbrook E. Kohrt;Ariane Thielens;Aurelien Marabelle;Aurelien Marabelle;Idit Sagiv-Barfi

  • Rationale for anti-OX40 cancer immunotherapy

    Sandrine Aspeslagh;Sophie Postel-Vinay;Sylvie Rusakiewicz;Jean-Charles Soria

  • Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

    M. Tazdait;L. Mezquita;J. Lahmar;R. Ferrara

Frequent Co-Authors

Laurence Zitvogel
Laurence Zitvogel University of Paris-Saclay
Caroline Robert
Caroline Robert University of Paris-Saclay
Jean-Charles Soria
Jean-Charles Soria Amgen (United States)
Olivier Lambotte
Olivier Lambotte University of Paris-Saclay
Benjamin Besse
Benjamin Besse University of Paris-Saclay
Guido Kroemer
Guido Kroemer Université Paris Cité
Ronald Levy
Ronald Levy Stanford University
Fabrice Andre
Fabrice Andre Institut Gustave Roussy
Laurence Albiges
Laurence Albiges Institut Gustave Roussy
David Planchard
David Planchard Institut Gustave Roussy

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those studying Immunology in the USA, pursuing related online degrees can broaden career opportunities in healthcare and research. Many students consider advanced nursing programs to complement their immunology expertise. For example, an acute care NP certification can open doors to specialized patient care roles, particularly in critical and urgent care settings.

If you’re interested in accelerating your nursing career, exploring a nurse practitioner accelerated program could be a practical step. These programs typically offer pathways to become a nurse practitioner more quickly, integrating clinical knowledge that complements immunology studies well.

For those without a nursing background, enrolling in online RN programs for non nurses is an accessible way to enter the nursing profession. Many of these programs are designed with flexibility for working adults and offer strong foundations relevant to immunological care and research.

Finally, students looking for less competitive entry points might explore the easiest accelerated nursing programs to get into. Such programs provide faster, more attainable routes into nursing, supporting diverse immunology-related career pathways in healthcare.

Best Scientists Citing Aurélien Marabelle

Trending Scientists